metformin has been researched along with insulin glargine in 188 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 45 (23.94) | 29.6817 |
| 2010's | 111 (59.04) | 24.3611 |
| 2020's | 32 (17.02) | 2.80 |
| Authors | Studies |
|---|---|
| Vehkavaara, S; Yki-Järvinen, H | 1 |
| Floyd, C; Harmon, C; Willoughby, DF | 1 |
| Janka, HU; Kliebe-Frisch, C; Plewe, G; Riddle, MC; Schweitzer, MA; Yki-Järvinen, H | 1 |
| Allen, E; Bode, B; Gabbay, RA; Garber, A; Hollander, P; Hu, P; Lewin, A; Raskin, P | 1 |
| Augendre-Ferrante, B; Bai, S; Campaigne, BN; Malone, JK; Reviriego, J | 1 |
| Campaigne, BN; Holcombe, JH; Kerr, LF; Malone, JK; Sachson, RA | 1 |
| Daneman, D; Perlman, K; Rachmiel, M | 1 |
| Hänninen, J; Hardy, K; Hulme, S; Kauppinen-Mäkelin, R; Lahdenperä, S; Lehtonen, R; Levänen, H; McNulty, S; Nikkilä, K; Ryysy, L; Tiikkainen, M; Tulokas, T; Vähätalo, M; Virtamo, H; Yki-Järvinen, H | 1 |
| Dailey, G; Rosenstock, J; Soltes-Rak, E; Stewart, JA; Strange, P; Sugimoto, D | 1 |
| Dempsey, E; Gerstein, HC; Harris, SB; Issa, M; Stewart, JA; Yale, JF | 1 |
| Malone, JK; Roach, P | 1 |
| Buchwald, A; Dellweg, S; Genova, P; Hausmann, M; Heinemann, L; Heise, T; Osborn, C; Rosskamp, R | 1 |
| Hamid, Z; Simmons, DL | 1 |
| Cersosimo, E; De Filippis, E; DeFronzo, RA; Gastaldelli, A; Glass, L; Miyazaki, Y; Triplitt, C; Wajcberg, E | 1 |
| Kann, PH; Medding, J; Moeller, J; Mokan, M; Mrevlje, F; Regulski, M; Szocs, A; Wascher, T; Zackova, V | 1 |
| Atabek, ME; Pirgon, O | 1 |
| Ashwell, SG; Dashora, UK; Home, PD; Sibal, L | 1 |
| Busch, K; Janka, HU; Plewe, G | 1 |
| Erdmann, E; Reuter, H | 1 |
| Högy, B; Janka, HU | 1 |
| Ali, O; Banerjee, S; Kelly, DF; Lee, PD | 1 |
| Mirza, SA | 1 |
| Müller, UA; Schiel, R | 2 |
| Barnett, AH; Brodows, R; Burger, J; Johns, D; Kendall, DM; Roberts, A; Trautmann, ME | 1 |
| Alagona, C; Chiavetta, A; Fedele, V; Leotta, C; Lorenti, I; Luca, S; Papa, G; Pezzino, V; Piro, S; Purrello, F; Rabuazzo, AM; Spadaro, L | 1 |
| Hessel, F; Janka, HU; Mã Ller, E; Walzer, S | 1 |
| Bergenstal, RM; Hollander, P; Johnson, M; Powers, MA; Rendell, M; Vlajnic, A; Wynne, A | 1 |
| Abourizk, N; Grevelink, J; Jones, N; Moore, AF; Soper, T | 1 |
| Doggrell, SA | 1 |
| Hermansen, K; Hermansen, ML; Mortensen, LS | 1 |
| Dorkhan, M; Frid, A; Groop, L | 1 |
| Beneduce, F; Ceriello, A; Ciotola, M; Esposito, K; Feola, G; Giugliano, D; Gualdiero, R; Maiorino, MI; Schisano, B | 1 |
| De Mattia, G; Laurenti, O; Moretti, A | 1 |
| Chan, JY; Frier, BM; Leyk, M; Tan, MH | 1 |
| Bunck, MC; Cornér, A; Deng, W; Diamant, M; Eliasson, B; Heine, RJ; Kendall, DM; Malloy, JL; Shaginian, RM; Smith, U; Taskinen, MR; Yki-Järvinen, H | 1 |
| Brodows, R; Cox, DJ; Crean, J; Johns, D; Kovatchev, B; McCall, AL | 1 |
| Rosenstock, J | 1 |
| Antic, S; Lalic, N; Ravn, GM; Russell-Jones, D; Schmitz, O; Sethi, BK; Simó, R; Vaag, A; Zdravkovic, M | 1 |
| Cook, NR; Everett, BM; Pradhan, AD; Ridker, PM; Rifai, N | 1 |
| Rigla Cros, M | 1 |
| Arnolds, S; Clair, J; Dain, MP; Dellweg, S; Kapitza, C; Nauck, MA; Rave, K | 1 |
| Borchert, M; Diessel, S; Forst, S; Forst, T; Hohberg, C; Larbig, M; Pfützner, A; Roth, W | 1 |
| Kress, S | 1 |
| Christensen, TE; Gundgaard, J; Thomsen, TL | 1 |
| Lavernia, F | 1 |
| Biedzinski, M; Boucherie, B; Charpentier, G; Dardari, D; Franc, S; Mistretta, F; Peschard, C; Petit, C; Requeda, E; Riveline, JP; Varroud-Vial, M | 1 |
| Minshall, ME; Sauriol, L; Tunis, SL | 1 |
| Meier, JJ; Nauck, MA | 2 |
| Hu, M; Luo, Y; Yang, X; Zhang, H; Zhang, L | 1 |
| Cripps, R; McFarland, MS | 1 |
| Balzi, D; Barchielli, A; Colombi, C; Dicembrini, I; Giannini, S; Mannucci, E; Marchionni, N; Melani, C; Monami, M; Romano, D; Rotella, CM; Vitale, V | 1 |
| Bergenstal, RM; Buse, JB; Glass, LC; Heilmann, CR; Hoogwerf, BJ; Kwan, AY; Lewis, MS; Rosenstock, J | 1 |
| Cersosimo, E; Cervera, A; DeFronzo, RA; Fernandez, M; Ghosh, S; Joya-Galeana, J; Musi, N; Reyna, S; Triplitt, C | 1 |
| Fonseca, V; Gill, J; Leahy, J; Zhou, R | 1 |
| Rosta, A | 1 |
| Petznick, A | 1 |
| Bunck, MC; Cornér, A; Diamant, M; Eliasson, B; Heine, RJ; Shaginian, RM; Smith, U; Taskinen, MR; Yki-Järvinen, H | 1 |
| Chowdhury, TA; Green, AN; Gupta, PS | 1 |
| Abdallah, M; Alickaj, A; Asad, S; Forte, V; Mahmud, S; McFarlane, SI; Pandey, A | 1 |
| Aasheim, ET; Fenske, WK; le Roux, CW; Miras, AD; Pournaras, DJ; Scholtz, S; Scopinaro, N | 1 |
| Chaudhuri, A; Dandona, P; DiGenio, A; Hollander, P; Ilgenfritz, J; McGill, JB; Meneghini, L; Riddle, M; Rosenstock, J | 1 |
| Abouelfath, A; Ambrosino, B; Bernard, MA; Blin, P; Droz, C; Dureau-Pournin, C; Gin, H; Lassalle, R; Le Jeunne, C; Moore, N; Pariente, A | 1 |
| Hofland, LJ; Janssen, JA; Lamberts, SW; Vähätalo, M; Varewijck, AJ; Yki-Järvinen, H | 1 |
| Böhm, F; Jarnert, C; Kalani, M; Rydén, L | 1 |
| Abbott, D; Lee, HK; Trask, LE | 1 |
| Nauck, MA | 1 |
| Karl, D; Riddle, M; Vlajnic, A; Zhou, R | 1 |
| Aalbers, J; Mohamed, F | 1 |
| Andreeff, M; Broglio, K; Busaidy, N; Cabanillas, ME; Ensor, J; Escalante, C; Faderl, S; Kantarjian, H; Konopleva, M; Lavis, V; O'Brien, S; Thomas, DA; Vu, K; Yeung, SC | 1 |
| Andreeff, M; Benito, JM; Chen, C; Fuentes-Mattei, E; Jin, Y; Konopleva, M; Lee, MH; Pan, J; Velazquez-Tores, G; Yeung, SC | 1 |
| Aschner, P; Chan, J; Dain, MP; Echtay, A; Fonseca, V; Owens, DR; Picard, S; Pilorget, V; Wang, E | 1 |
| Diamant, M | 1 |
| Forst, T; Larbig, M; Pfützner, A; Pscherer, S; von Stritsky, B | 1 |
| Einecke, D | 1 |
| Ampudia-Blasco, FJ; Andjelkovic, M; Balena, R; Boldrin, M; Horton, E; Nauck, M; Parusel, CT | 1 |
| Chari, ST; Muniraj, T | 1 |
| Antenore, A; Bagnoli, P; Dicembrini, I; Filippi, L; Mannucci, E; Marchionni, N; Monami, M; Rotella, CM; Sgrilli, F; Ungar, A | 1 |
| Demissie, M; Hollander, P; Kesavadev, J; Meneghini, L; Nazeri, A | 1 |
| Forst, T; Hanefeld, M; Köhler, C; Landgraf, W; Pistrosch, F; Schaper, F | 1 |
| Schumm-Draeger, PM | 1 |
| Karagianni, P; Kartali, N; Polyzos, SA; Sambanis, C; Zografou, I | 1 |
| Buse, JB; Kahn, SE; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Staten, M; Wexler, D | 1 |
| Moniri, NH; Ryan, GJ; Smiley, DD | 1 |
| Huang, Q; Peng, Y; Wang, Y; Zhao, L | 1 |
| Ameer, B; Aurand, L; Dailey, G; Stewart, J; Zhou, R | 1 |
| Lenart-Lipińska, M; Matyjaszek-Matuszek, B; Nowakowski, A; Rogalska, D | 1 |
| Bramlage, P; Fleischmann, H; Hanefeld, M; Schiffhorst, G | 1 |
| Bramlage, P; Pegelow, K; Seufert, J | 1 |
| Fathy, A; Khashab, S; Shaheen, N; Soliman, AR; Soliman, MA | 1 |
| Cariou, B; Handelsman, Y; Mathieu, C; Rana, A; Rodbard, HW; Wolden, ML; Zinman, B | 1 |
| Birkeland, KI; Bordeleau, L; Bosch, J; Chang Yu, P; Dagenais, GR; Gerstein, HC; Keltai, M; Marin-Neto, JA; Pirags, V; Probstfield, J; Ratner, RE; Riddle, MC; Rosenstock, J; Ryden, LE; Spinas, GA; Yakubovich, N; Yusuf, S | 1 |
| Chon, S; Kang, JG; Lee, CB; Noh, J; Oh, SJ; Park, CY; Park, SW | 1 |
| Cleall, S; Gross, JL; Onaca, A; Rodríguez, A; Tinahones, FJ | 1 |
| Cheng, Q; Deng, H; Feng, Z; Gong, L; Li, Q; Li, R; Long, J; Luo, C; Qing, H; Wang, Z; Yang, S; Ye, P; Zhang, S; Zhao, C; Zhou, B | 1 |
| Ahrén, B; Chow, FC; Fonseca, VA; Gross, JL; Johnson, SL; Leiter, LA; Miller, D; Ratner, RE; Rosenstock, J; Stewart, MW; Yang, F | 1 |
| Bolli, GB; Candelas, C; Dain, MP; Deerochanawong, C; Home, PD; Landgraf, W; Mathieu, C; Pilorget, V; Riddle, MC | 1 |
| Agarwal, SK; Singh, BK; Wadhwa, R | 1 |
| Cleall, S; de Vries, D; Diamant, M; Hoogwerf, BJ; MacConell, L; Malone, JK; Nauck, MA; Reaney, M; Shaginian, R; Wolffenbuttel, BH | 1 |
| Dain, MP; Landgraf, W; Owens, DR; Traylor, L | 1 |
| Carr, MC; Cirkel, DT; Perry, C; Pratley, R; Stewart, M; Weissman, PN; Ye, J | 1 |
| Buse, JB; Diamant, M; Donsmark, M; Furber, S; Han, J; MacConell, L; Maggs, D; Peters, A; Russell-Jones, D | 1 |
| Candelas, C; Charbonnel, B; D'Alessio, D; Dain, MP; de Pablos-Velasco, P; Häring, HU; Pilorget, V; Vincent, M; Yki-Järvinen, H | 1 |
| Bueno, M; Lecube, A; Suárez, X | 1 |
| Ahn, KJ; Bao, Y; Chen, L; Chuang, LM; Gao, F; Ji, Q; Jia, W; Li, P; Pang, C; Tu, Y; Xiao, X; Yang, J | 1 |
| Castel, H; Chartrand, G; Chiasson, JL; de Guise, J; Gilbert, G; Julien, AS; Massicotte-Tisluck, K; Olivié, D; Rabasa-Lhoret, R; Soulez, G; Tang, A; Wartelle-Bladou, C | 1 |
| Coester, HV; Delfolie, A; Forst, T; Hincelin-Méry, A; Kapitza, C; Meier, JJ; Menge, BA; Rosenstock, J; Roy-Duval, C | 1 |
| Agha, A; Ashley, DT; Cummins, PM; Davenport, C; Forde, H; Mahmood, WA; McAdam, B; McDermott, J; McGrath, F; Smith, D; Sreenan, S; Thompson, CJ | 1 |
| Bergenstal, R; Branch, KR; Davis, B; Hirsch, I; Khakpour, D; Kingry, C; O'Brien, K; Pressel, S; Probstfield, JL; Riddle, M | 1 |
| Benroubi, M; Giorgino, F; Pechtner, V; Sun, JH; Zimmermann, AG | 1 |
| Bertrand, JH; Catargi, B; Douard, H; Feige, JM; Fischbach, M; Iliou, MC; Patois-Vergès, B; Simoneau-Robin, I; Vergès, B | 1 |
| Chen, C; Chen, P; Huang, Q; Shao, Z; Wang, S; Xu, X; Yan, L | 1 |
| Gao, L; Gill, J; Reid, T; Rhinehart, A; Stuhr, A; Traylor, L; Vlajnic, A | 1 |
| Tong, N; Zhang, L; Zhang, M; Zhang, Y | 1 |
| Buse, JB; García-Hernández, P; Lehmann, L; Lingvay, I; Norwood, P; Pérez Manghi, F; Tarp-Johansen, MJ | 1 |
| Gupta, Y; Kalra, S | 1 |
| Cao, J; Ji, M; Xia, L; Zou, D | 1 |
| Gross, JL; Hansen, CT; Lv, X; Pan, C; Sun, L; Wagner, R; Xu, H; Yang, W | 1 |
| Chung, CH; Duan, R; Edralin, DM; Han, JH; Jeong, IK; Rodriguez, A; Zhou, Z | 1 |
| Valek, R; Von der Mark, J | 1 |
| Aronson, R; Gentile, S; Guerci, B; Hanefeld, M; Heller, S; Perfetti, R; Rosenstock, J; Roy-Duval, C; Souhami, E; Tinahones, FJ; Wardecki, M; Ye, J | 1 |
| Aroda, VR; Diamant, M; Fonseca, V; Perfetti, R; Rosenstock, J; Silvestre, L; Souhami, E; Zhou, T | 1 |
| Bastyr, EJ; Bue-Valleskey, JM; Chang, AM; Cusi, K; Hartman, ML; Haupt, A; Higdon, AN; Hoogwerf, BJ; Jacober, SJ; Sanyal, AJ; Zhang, S | 1 |
| de Lapertosa, SB; Frechtel, G; Hardy, E; Sauque-Reyna, L | 1 |
| Garhyan, P; Gastaldelli, A; Heise, T; Hoevelmann, U; Jacober, SJ; Knadler, MP; Lam, EC; Linnebjerg, H; Plum-Moerschel, L; Porksen, N; Watkins, E | 1 |
| Ford, RJ; Gerstein, HC; Haenel, H; Hess, S; Lee, S; McQueen, M; Pare, G; Raman, K; Sjaarda, J; Steinberg, GR | 1 |
| Anglin, G; Barkin, JS; Frossard, JL; Harper, KD; Hensley, IE; Milicevic, Z; Nauck, MA | 1 |
| Balasubramanian, K; Gerstein, HC; Hall, S; McInnes, N; Otto, R; Punthakee, Z; Sherifali, D; Smith, A; Vandermey, J | 1 |
| Aroda, VR; Axelsen, M; Bain, SC; Cariou, B; DeVries, JH; Piletič, M; Rose, L; Rowe, E | 1 |
| Machado-Alba, JE; Machado-Duque, ME; Ramírez-Riveros, AC | 1 |
| Chandarana, K; Harris, S; Jaeckel, E; Jódar, E; Lingvay, I; Ranthe, MF | 1 |
| Scott, LJ | 1 |
| Chien, JY; Johnson, J; Ma, X; Malone, J; Sinha, V | 1 |
| Boye, KS; Brunt, KV; Milicevic, Z; Varnado, O; Yu, M | 1 |
| Cook, NR; Everett, BM; Pradhan, AD; Ridker, PM; Srivastava, PK | 1 |
| Choi, H; Kramer, CK; Retnakaran, R; Ye, C; Zinman, B | 1 |
| Du, X; Hu, C; Lu, W; Lu, Z; Shao, X; Shi, B | 1 |
| Filippova, E; Gu, L; Li, P; Nevárez, L; Song, KH; Tao, B; Wang, F; Wang, W; Yang, J | 1 |
| Deng, H; Dou, J; Hong, T; Huang, Q; Kang, Z; Kuang, H; Li, Y; Luo, S; Qin, G; Shan, Z; Tan, Y; Weng, J; Xiao, X; Xu, F; Xu, W; Yan, J; Yang, W; Yang, X; Yao, B; Yuan, H; Zeng, L | 1 |
| Darmiento, C; Duran-García, S; Engel, SS; Gantz, I; Golm, GT; Kaufman, KD; Lam, RLH; O'Neill, EA; Roussel, R; Shah, S; Shankar, RR; Zhang, Y | 1 |
| Bailey, TS; Boëlle-Le Corfec, E; Bonadonna, RC; Brulle-Wohlhueter, C; Choudhary, P; Yale, JF | 1 |
| Bosch, J; Cukierman-Yaffe, T; Gerstein, HC; Jung, H; Punthakee, Z | 1 |
| Weng, J | 1 |
| Upala, S | 1 |
| Cusi, K | 1 |
| Taneja, V | 1 |
| Weng, J; Yan, J; Yang, D | 1 |
| Bosch, A; Bramlage, P; Jung, S; Kannenkeril, D; Karg, MV; Ott, C; Schmieder, RE; Striepe, K | 1 |
| Bargiota, A; Billings, L; Cannon, AJ; Doshi, A; Hunt, B; Leiter, LA; Malkin, S; Mocarski, M; Ranthe, MF; Schiffman, A | 1 |
| Emery, A; Retnakaran, R | 1 |
| Dronamraju, N; Ekholm, E; Garcia-Sanchez, R; Jabbour, SA; Johnsson, E; Lind, M; Vilsbøll, T | 1 |
| Aronson, R; Gerstein, HC; Hall, S; Harris, S; Hramiak, I; Liu, YY; McInnes, N; Sigal, RJ; Sultan, F; Woo, V | 1 |
| Díaz-Toscano, ML; Fernández-Rodarte, K; González-Gálvez, G; Llamas-Moreno, JF; Sañudo-Maury, ME | 1 |
| Arnau Vives, MA; Ballesteros Martin-Portugués, A; Catalá Gregori, A; Caudet Esteban, J; Cerveró Rubio, A; Del Olmo-García, MI; Hervás Marín, D; Merino-Torres, JF; Penalba Martínez, M | 1 |
| Rasouli, N | 1 |
| Bajaj, HS; Begtrup, K; Goldenberg, R; Hansen, MV; Janež, A; Jia, T; Rosenstock, J; Silver, R | 1 |
| Guo, W; Lin, L; Tian, W; Xu, X | 1 |
| Shankar, A | 1 |
| Chen, X; Duan, Y; He, W; Hu, J; Hu, S; Li, W; Liao, Y; Lin, M; Liu, L; Liu, P; Liu, Z; Ma, J; Shao, S; Shen, L; Xu, Y; Xue, Y; Yin, P; Yu, X; Zeng, J; Zeng, Z; Zhang, J; Zhao, S; Zhao, T | 1 |
| Emery, A; Gerstein, HC; Harris, SB; Kramer, CK; McInnes, N; Reichert, SM; Retnakaran, R; Thorpe, KE; Ye, C; Zinman, B | 1 |
| Arslanian, S; Atkinson, K; Barengolts, E; Brooks-Worrell, BM; Buchanan, TA; Edelstein, SL; Kahn, SE; Mather, KJ; Nadeau, KJ; Palmer, JP; Palomino, B; Tjaden, AH; Utzschneider, KM | 1 |
| Amarin, JZ; Beirat, AF; Hasan, YY; Hassoun Al Najar, AM; Qtaishat, A; Tierney, ME; Zaghlol, LY; Zaghlol, RY; Zayed, AA | 1 |
| Bosch, A; Bramlage, P; Jung, S; Kannenkeril, D; Kolwelter, J; Korn, M; Ott, C; Schiffer, M; Schmieder, RE; Striepe, K | 1 |
| Braga, M; Gerstein, HC; Goldenberg, R; Gupta, N; Hall, S; Hramiak, I; Liu, YY; McInnes, N; Otto, R; Rabasa-Lhoret, R; Sherifali, D; Sigal, RJ; Smith, A; Sultan, F; Woo, V | 1 |
| Bray, R; Dahl, D; Huh, R; Norwood, P; Onishi, Y; Patel, H; Rodríguez, Á | 1 |
| Dex, T; Ferrannini, E; Mari, A; Niemoeller, E; Servera, S | 1 |
| Chen, L; Cheng, Z; Dong, X; Gu, S; Li, Q; Liu, M; Niemoeller, E; Ping, L; Souhami, E; Xiao, J; Yang, W; Yuan, G | 1 |
| Jacob, S; Kaltoft, MS; Kellerer, M; Lawson, J; Nielsen, LL; Strojek, K; Tabak, Ö | 1 |
| Cui, N; Feng, W; Guo, L; Jiang, C; Li, Y; Liang, L; Liu, J; Mu, Y; Pan, Q; Wan, H; Wang, G; Wang, J; Wang, T; Xu, B; Zhang, X | 1 |
| Ali, RH; Ali, SK | 1 |
| Balasubramanyam, A; Burch, HB; Buse, JB; Butera, NM; Cohen, RM; Crandall, JP; Kahn, SE; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Rasouli, N; Tiktin, M; Wexler, DJ; Younes, N | 1 |
| Bebu, I; Burch, HB; Buse, JB; Cherrington, AL; Fortmann, SP; Green, JB; Kahn, SE; Kirkman, MS; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Phillips, LS; Pop-Busui, R; Steffes, M; Tiktin, M; Tripputi, M; Wexler, DJ; Younes, N | 1 |
| Crown, W; Deng, Y; Dhruva, SS; Gandotra, C; Herrin, J; Lyon, TD; McCoy, RG; Noseworthy, P; Polley, EC; Quinto, K; Ross, JS; Shah, ND; Wallach, JD; Yao, X | 1 |
| Cauchon, M; Lanthier, L; Mutchmore, A; Plourde, MÉ | 1 |
| Brown, K; Donato, AA | 1 |
| Bebu, I; de Boer, IH; Ghosh, A; Inzucchi, SE; Ismail-Beigi, F; McGill, JB; Mudaliar, S; Schade, D; Steffes, MW; Tamborlane, WV; Tan, MH; Wexler, DJ; Younes, N | 1 |
| Azharuddin, M; Gerstein, HC; Hall, S; Harris, SB; Hramiak, I; Liu, YY; Liutkus, JF; Lochnan, HA; McInnes, N; Otto, RE; Punthakee, Z; Sherifali, D; Sigal, RJ; Smith, A; Sultan, F; Yale, JF | 1 |
16 review(s) available for metformin and insulin glargine
| Article | Year |
|---|---|
A lesson in early morning hyperglycemia.
Topics: Blood Glucose Self-Monitoring; Circadian Rhythm; Diabetes Complications; Dose-Response Relationship, Drug; Glucagon; Human Growth Hormone; Humans; Hydrocortisone; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Somatomedins; Time Factors | 2004 |
Insulin analogues in children and teens with type 1 diabetes: advantages and caveats.
Topics: Adolescent; Amyloid; Child; Diabetes Mellitus, Type 1; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Islet Amyloid Polypeptide; Metformin | 2005 |
[Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus].
Topics: Amino Acid Sequence; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Exenatide; Gastric Emptying; Gastrointestinal Diseases; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Receptors, Glucagon; Sulfonylurea Compounds; Venoms | 2007 |
Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease.
Topics: C-Reactive Protein; Cardiovascular Diseases; Diabetic Angiopathies; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Isophane; Insulin, Long-Acting; Metformin; Postprandial Period; Risk Assessment; Risk Factors; Thiazolidinediones | 2008 |
Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Neoplasms; Risk | 2010 |
An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.
Topics: Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Prospective Studies; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Treatment Outcome | 2011 |
[Diabetes and cancer risk: oncologic considerations].
Topics: Adipokines; Age Factors; Animals; Cytokines; Diabetes Complications; Diabetes Mellitus, Type 2; Feeding Behavior; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Incidence; Insulin; Insulin Glargine; Insulin Resistance; Insulin, Long-Acting; Metformin; Motor Activity; Neoplasms; Obesity; Prevalence; Research Design; Risk Factors; Sex Factors; Smoking; Sulfonylurea Compounds; Thiazolidinediones | 2011 |
[Hypoglycemia].
Topics: Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gliclazide; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Risk Factors | 2011 |
Diabetes mellitus and the risk of cancer.
Topics: Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Insulins; Metformin; Neoplasms; Risk Assessment; Risk Factors | 2011 |
The design of the liraglutide clinical trial programme.
Topics: Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2012 |
Diabetes and pancreatic cancer.
Topics: Age Factors; Body Mass Index; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Early Detection of Cancer; Evidence-Based Medicine; Global Health; Glucose Intolerance; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Meta-Analysis as Topic; Metformin; Obesity; Pancreatic Neoplasms; Prevalence; Risk Assessment; Risk Factors | 2012 |
Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Diabetes Mellitus; Ethanolamines; Female; Humans; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Myocardial Ischemia; Nebivolol; Neoplasms; Propanolamines; Risk | 2013 |
Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
Topics: Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Evidence-Based Medicine; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2013 |
Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Treatment Outcome | 2014 |
[Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
Topics: Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Female; Gastrointestinal Diseases; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pioglitazone; Receptors, Glucagon; Thiazolidinediones; Venoms; Weight Loss | 2014 |
Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Insulin Glargine; Liraglutide; Metformin; Patient Safety; Peptides; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Sitagliptin Phosphate; Treatment Outcome; Venoms | 2016 |
111 trial(s) available for metformin and insulin glargine
| Article | Year |
|---|---|
3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes.
Topics: Acetylcholine; Adult; Aged; Blood Flow Velocity; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Endothelium, Vascular; Female; Humans; Insulin; Insulin Glargine; Insulin, Long-Acting; Lipids; Male; Matched-Pair Analysis; Metformin; Middle Aged; Nitroprusside; Reproducibility of Results; Time; Vasodilation | 2004 |
Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Weight Gain | 2005 |
Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Aspart; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Treatment Outcome | 2005 |
Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Circadian Rhythm; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Delivery Systems; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin Lispro; Insulin, Long-Acting; Male; Metformin; Middle Aged; Weight Gain | 2005 |
Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.
Topics: Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin Lispro; Insulin, Long-Acting; Male; Metformin; Middle Aged | 2004 |
Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Insulin; Insulin Glargine; Insulin, Isophane; Insulin, Long-Acting; Lipid Metabolism; Liver; Male; Metformin; Middle Aged | 2006 |
Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Lipids; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Canada; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome | 2006 |
Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Eating; Fatty Acids, Nonesterified; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin Lispro; Insulin, Long-Acting; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome; Triglycerides | 2006 |
Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Pilot Projects; Sulfonylurea Compounds; Treatment Failure | 2006 |
Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Topics: Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liver; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride.
Topics: Aged; Biphasic Insulins; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Aspart; Insulin Glargine; Insulin, Isophane; Insulin, Long-Acting; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome | 2006 |
Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Blood Glucose; Blood Glucose Self-Monitoring; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Time Factors | 2007 |
Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Sulfonylurea Compounds; Weight Gain | 2007 |
Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with Type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pilot St
Topics: Aged; Body Mass Index; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Patient Satisfaction; Pilot Projects; Sulfonylurea Compounds; Treatment Outcome | 2008 |
Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the Switch pilot st
Topics: Administration, Oral; Aged; Blood Glucose; Body Mass Index; Case-Control Studies; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Pilot Projects; Prospective Studies; Sulfonylurea Compounds; Time Factors | 2007 |
Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
Topics: Adult; Blood Glucose; Body Weight; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Resistance; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Peptides; Sulfonylurea Compounds; Venoms | 2007 |
Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs.
Topics: Administration, Oral; Aged; Blood Glucose; Body Mass Index; Carbamates; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Pioglitazone; Piperidines; Research Design; Rosiglitazone; Thiazolidinediones | 2008 |
Insulin glargine added to therapy with oral antidiabetic agents improves glycemic control and reduces long-term complications in patients with type 2 diabetes - a simulation with the Diabetes Mellitus Model (DMM).
Topics: Adult; Aged; Computer Simulation; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Middle Aged; Models, Biological; Sulfonylurea Compounds | 2007 |
Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine.
Topics: Adult; Aged; Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dose-Response Relationship, Drug; Drug Administration Schedule; Eating; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Racial Groups; United States | 2008 |
Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes: what to add--insulin glargine or pioglitazone?
Topics: Adiponectin; Adult; Aged; Benzamides; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Heart Function Tests; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin Resistance; Insulin, Long-Acting; Metformin; Middle Aged; Pioglitazone; Proinsulin; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Young Adult | 2008 |
Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Protamines; Sulfonylurea Compounds; Weight Gain | 2008 |
Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study.
Topics: Administration, Oral; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Isophane; Insulin, Long-Acting; Male; Metformin; Middle Aged; Monitoring, Ambulatory; Pilot Projects | 2009 |
Relationship between HbA1c and hypoglycaemia in patients with type 2 diabetes treated with different insulin regimens in combination with metformin.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin Lispro; Insulin, Long-Acting; Male; Metformin; Middle Aged | 2009 |
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.
Topics: Arginine; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin Secretion; Insulin-Secreting Cells; Insulin, Long-Acting; Kinetics; Male; Metformin; Middle Aged; Peptides; Venoms | 2009 |
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Placebos; Sulfonylurea Compounds; Young Adult | 2009 |
Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial.
Topics: Biomarkers; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Interleukin-6; Male; Metformin; Middle Aged; Receptors, Tumor Necrosis Factor, Type II | 2009 |
Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Follow-Up Studies; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Peptides; Treatment Outcome; Venoms | 2010 |
Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial beta-cell protection in individuals with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin-Secreting Cells; Insulin, Isophane; Insulin, Long-Acting; Male; Metformin; Middle Aged; Pilot Projects; Postprandial Period | 2010 |
Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.
Topics: Canada; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Quality-Adjusted Life Years; Sulfonylurea Compounds | 2010 |
[Comparison on efficacy and safety of two regimens for treatment of type 2 diabetes mellitus: glargine plus metformin versus neutral protamine hagedorn plus metformin].
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Isophane; Insulin, Long-Acting; Male; Metformin; Middle Aged | 2010 |
Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
Topics: Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Sensitivity and Specificity; Thiazolidinediones; Venoms | 2011 |
Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects.
Topics: Adult; Body Mass Index; Carotid Arteries; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation Mediators; Insulin; Insulin Glargine; Insulin Resistance; Insulin, Long-Acting; Male; Metformin; Mexican Americans; Middle Aged; Muscle, Skeletal; Myositis; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Tunica Intima | 2011 |
Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin-Secreting Cells; Insulin, Long-Acting; Male; Metformin; Middle Aged; Peptides; Venoms | 2011 |
Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2012 |
Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin-Like Growth Factor I; Insulin, Isophane; Insulin, Long-Acting; Male; Metformin; Middle Aged | 2012 |
Strict glycaemic control improves skin microcirculation in patients with type 2 diabetes: a report from the Diabetes mellitus And Diastolic Dysfunction (DADD) study.
Topics: Administration, Oral; Aged; Biomarkers; Blood Glucose; Brachial Artery; Carbamates; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diastole; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Aspart; Insulin Glargine; Insulin, Long-Acting; Laser-Doppler Flowmetry; Male; Metformin; Microcirculation; Middle Aged; Piperidines; Prospective Studies; Regional Blood Flow; Skin; Sweden; Time Factors; Treatment Outcome; Vasodilation; Ventricular Dysfunction; Ventricular Function | 2012 |
Fasting plasma glucose 6-12 weeks after starting insulin glargine predicts likelihood of treatment success: a pooled analysis.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Prognosis; Prospective Studies; Time Factors; Treatment Outcome | 2012 |
A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Burkitt Lymphoma; C-Peptide; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Prospective Studies; Thiazolidinediones; Treatment Outcome; Vincristine; Young Adult | 2012 |
Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.
Topics: Adult; Aged; Body Weight; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Peptides; Treatment Outcome; Young Adult | 2013 |
Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Diabetes Mellitus; Ethanolamines; Female; Humans; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Myocardial Ischemia; Nebivolol; Neoplasms; Propanolamines; Risk | 2013 |
Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes.
Topics: Argentina; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Detemir; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Patient Satisfaction; Republic of Korea; Thailand; Treatment Outcome; United States | 2013 |
Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin Secretion; Insulin-Secreting Cells; Insulin, Long-Acting; Male; Metformin; Microvessels; Middle Aged; Prospective Studies | 2013 |
Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy.
Topics: Anthropometry; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Lipids; Male; Metformin; Middle Aged; Multivariate Analysis; Peptides; Prospective Studies; Treatment Outcome; Venoms | 2013 |
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).
Topics: Adult; Blood Glucose; Comparative Effectiveness Research; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Outcome Assessment, Health Care; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2013 |
Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Exenatide; Female; Glycated Hemoglobin; Headache; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Nausea; Peptides; Sulfonylurea Compounds; Venoms; Vomiting | 2013 |
Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Kidney Transplantation; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Gain; Weight Loss | 2013 |
Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Health Status; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Metformin; Treatment Outcome | 2014 |
The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia.
Topics: Antineoplastic Agents; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Omega-3; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Metformin; Middle Aged; Neoplasms | 2014 |
Comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Insulin Glargine; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Young Adult | 2014 |
Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Insulin Lispro; Insulin, Long-Acting; Male; Meals; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Treatment Outcome | 2014 |
Efficacy of metformin-based oral antidiabetic drugs is not inferior to insulin glargine in newly diagnosed type 2 diabetic patients with severe hyperglycemia after short-term intensive insulin therapy.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; China; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin-Secreting Cells; Insulin, Long-Acting; Male; Metformin; Middle Aged; Prognosis; Quality of Life; Risk Factors | 2015 |
Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin Lispro; Insulin, Long-Acting; Male; Meals; Metformin; Middle Aged; Pioglitazone; Receptors, Glucagon; Thiazolidinediones; Treatment Outcome | 2014 |
Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
Topics: Aged; Asia; Blood Glucose Self-Monitoring; Circadian Rhythm; Diabetes Mellitus, Type 2; Drug Dosage Calculations; Drug Resistance; Drug Therapy, Combination; Europe; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Insulin, Isophane; Insulin, Long-Acting; Male; Metformin; Middle Aged; Middle East; South Africa; Sulfonylurea Compounds | 2015 |
Study of optimal basal insulin glargine dose requirement in Indian population as an add on therapy to oral hypoglycaemic agents to achieve target fasting blood glucose levels.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Humans; Hypoglycemia; Hypoglycemic Agents; India; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Pioglitazone; Prospective Studies; Sulfonylurea Compounds; Thiazolidinediones | 2013 |
Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
Topics: Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedule; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin Lispro; Insulin, Long-Acting; Male; Meals; Metformin; Middle Aged; Peptides; Quality of Life; Receptors, Glucagon; Treatment Outcome; Venoms | 2014 |
HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Retreatment; Sulfonylurea Compounds; Treatment Outcome; Young Adult | 2014 |
Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.
Topics: Administration, Oral; Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; International Cooperation; Liraglutide; Male; Metformin; Middle Aged; Treatment Outcome | 2015 |
Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily pre
Topics: Acarbose; Aged; China; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Inositol; Insulin Glargine; Insulin Lispro; Male; Metformin; Middle Aged; Republic of Korea; Taiwan; Treatment Outcome | 2015 |
Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial.
Topics: Adipose Tissue; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Liver; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Liver; Magnetic Resonance Imaging; Male; Metformin; Middle Aged | 2015 |
Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gastric Emptying; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Male; Metformin; Middle Aged; Peptides; Postprandial Period; Treatment Outcome | 2015 |
Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes.
Topics: Albuminuria; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Peptides; Postprandial Period; Risk Factors; Time Factors; Venoms | 2015 |
Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastrointestinal Diseases; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin Glargine; Male; Metformin; Middle Aged; Recombinant Fusion Proteins; Sulfonylurea Compounds; Treatment Outcome; Weight Loss | 2015 |
Influence of glycemic control on gain in VO2 peak, in patients with type 2 diabetes enrolled in cardiac rehabilitation after an acute coronary syndrome. The prospective DARE study.
Topics: Acute Coronary Syndrome; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Exercise Therapy; Female; Fructosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Aspart; Insulin Glargine; Male; Metformin; Middle Aged; Oxygen Consumption; Pulmonary Gas Exchange; Pulmonary Ventilation; Treatment Outcome | 2015 |
[The efficacy and safety of human glucagon-like peptide-1 analogue liraglutide in newly diagnosed type 2 diabetes with glycosylated hemoglobin A1c > 9].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Metformin; Treatment Outcome | 2015 |
Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE).
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dietary Supplements; Fatty Acids, Omega-3; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Middle Aged; Proportional Hazards Models; Risk Factors; Sulfonylurea Compounds; Treatment Outcome | 2016 |
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
Topics: Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Weight Gain; Weight Loss | 2016 |
Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes.
Topics: Adult; Aged; Body Mass Index; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Middle Aged; Obesity; Sitagliptin Phosphate; Treatment Outcome | 2016 |
A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.
Topics: Blood Glucose; China; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Treatment Outcome | 2016 |
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.
Topics: Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endpoint Determination; Female; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Male; Meals; Metformin; Middle Aged; Overweight; Peptides; Postprandial Period | 2016 |
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.
Topics: Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Middle Aged; Peptides; Postprandial Period; Risk; Safety | 2016 |
The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial.
Topics: Adult; Aged; Argentina; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedule; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Insulin Lispro; Male; Metformin; Mexico; Middle Aged; Peptides; Retrospective Studies; Treatment Outcome; United States; Venoms | 2016 |
Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.
Topics: Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin Lispro; Insulin Resistance; Liver; Male; Meals; Metformin; Middle Aged; Polyethylene Glycols; Treatment Outcome | 2017 |
Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial.
Topics: Acarbose; Aged; Ambulatory Care; Blood Glucose; Diabetes Mellitus, Type 2; Diet, Reducing; Exercise; Feasibility Studies; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Life Style; Male; Metformin; Middle Aged; Pilot Projects; Remission Induction; Weight Reduction Programs | 2017 |
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, mul
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Middle Aged | 2017 |
Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.
Topics: Anti-Obesity Agents; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Combinations; Drug Monitoring; Drug Resistance, Multiple; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Metformin; Obesity; Overweight; Weight Gain; Weight Loss | 2018 |
Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Metformin; Peptides | 2017 |
Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9).
Topics: Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin Glargine; Male; Metformin; Middle Aged; Patient Reported Outcome Measures; Quality of Life; Recombinant Fusion Proteins | 2017 |
Randomized Trial of the Effects of Insulin and Metformin on Myocardial Injury and Stress in Diabetes Mellitus: A Post Hoc Exploratory Analysis.
Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Risk Factors; Troponin T | 2017 |
Two-year trial of intermittent insulin therapy vs metformin for the preservation of β-cell function after initial short-term intensive insulin induction in early type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin Lispro; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pilot Projects; Treatment Outcome | 2018 |
Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance.
Topics: Adiposity; Adult; Aged; Blood Glucose; Body Fat Distribution; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Humans; Insulin Glargine; Insulin Resistance; Insulin, Long-Acting; Intra-Abdominal Fat; Male; Metformin; Middle Aged; Obesity, Abdominal; Peptides; Venoms | 2018 |
Impact of Insulin and Metformin Versus Metformin Alone on β-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.
Topics: Adolescent; Age Factors; Blood Glucose; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Insulin; Insulin Glargine; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Young Adult | 2018 |
Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial.
Topics: Adult; Aged; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Immunoglobulin Fc Fragments; Insulin Glargine; Male; Metformin; Mexico; Middle Aged; Recombinant Fusion Proteins; Republic of Korea; Russia; Sulfonylurea Compounds; Treatment Outcome | 2019 |
Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Topics: Adult; Aged; Blood Glucose; Body Weight; Comorbidity; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Linear Models; Lipid Metabolism; Liraglutide; Male; Metformin; Middle Aged; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Prognosis; Prospective Studies; Sitagliptin Phosphate; Treatment Outcome | 2019 |
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
Topics: Aged; Deprescriptions; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Least-Squares Analysis; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome | 2019 |
Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patient-level pooled analysis of EDITION 1, 2 and 3.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemia; Insulin Glargine; Intention to Treat Analysis; Male; Metformin; Middle Aged; Young Adult | 2019 |
Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial.
Topics: Aged; Cardiovascular Diseases; Cognitive Dysfunction; Educational Status; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin Glargine; Male; Metformin; Middle Aged; Proportional Hazards Models; Prospective Studies; Risk Factors | 2019 |
Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes.
Topics: Aged; Arterial Pressure; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Germany; Glucosides; Humans; Insulin Glargine; Linagliptin; Male; Metformin; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Vascular Stiffness | 2020 |
Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.
Topics: Adult; Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Combinations; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Metformin; United States | 2020 |
Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial.
Topics: Adamantane; Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Treatment Outcome | 2020 |
Remission of Type 2 Diabetes Following a Short-term Intervention With Insulin Glargine, Metformin, and Dapagliflozin.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exercise; Female; Glucosides; Glycated Hemoglobin; Healthy Lifestyle; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Middle Aged; Recurrence; Remission Induction; Secondary Prevention; Time Factors; Treatment Outcome | 2020 |
Mexican population sub-analysis of the lixilan clinical program with the fixed ratio combination of insulin glargine and lixisenatide (iGlarLixi).
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Ethnicity; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Mexico; Middle Aged; Peptides; Treatment Outcome | 2020 |
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged | 2020 |
Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
Topics: Adult; Blood Glucose; Body Weight; China; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Intra-Abdominal Fat; Liraglutide; Liver; Male; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity; Prospective Studies; Subcutaneous Fat; Treatment Outcome; Weight Loss | 2020 |
An Efficacy and Safety Study of Remogliflozin in Obese Indian Type 2 Diabetes Mellitus Patients Who Were Inadequately Controlled on Insulin Glargine Plus other Oral Hypoglycemic Agents.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Metformin; Obesity; Pharmaceutical Preparations; Retrospective Studies | 2021 |
Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Insulin; Insulin Aspart; Insulin Glargine; Metformin | 2021 |
Short-term intensive insulin as induction and maintenance therapy for the preservation of beta-cell function in early type 2 diabetes (RESET-IT Main): A 2-year randomized controlled trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Regular, Human; Metformin | 2021 |
Islet Autoimmunity in Adults With Impaired Glucose Tolerance and Recently Diagnosed, Treatment Naïve Type 2 Diabetes in the Restoring Insulin SEcretion (RISE) Study.
Topics: Autoantibodies; Autoantigens; Autoimmunity; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Glargine; Islets of Langerhans; Liraglutide; Metformin; T-Lymphocytes | 2021 |
Effect of Dosage Reduction of Hypoglycemic Multidrug Regimens on the Incidences of Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramaḍān: A Randomized Controlled Trial.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycemic Control; Humans; Hypoglycemic Agents; Insulin Glargine; Islam; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Vildagliptin | 2021 |
Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Germany; Glomerular Filtration Rate; Glucosides; Hemodynamics; Humans; Hypoglycemic Agents; Insulin Glargine; Linagliptin; Male; Metformin; Middle Aged; Prospective Studies; Renal Plasma Flow; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2021 |
Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Metformin; Sitagliptin Phosphate; Treatment Outcome | 2022 |
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Glargine; Male; Metformin; Middle Aged; Weight Loss | 2022 |
Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Combinations; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Metformin; Peptides | 2022 |
Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
Topics: Administration, Oral; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Metformin; Middle Aged; Peptides; Sodium-Glucose Transporter 2 Inhibitors; Weight Gain | 2022 |
Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Aspart; Insulin Glargine; Metformin; Treatment Outcome | 2022 |
Efficacy and safety of a basal insulin + 2-3 oral antihyperglycaemic drugs regimen versus a twice-daily premixed insulin + metformin regimen after short-term intensive insulin therapy in individuals with type 2 diabetes: The multicentre, open-label, rando
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Regular, Human; Metformin | 2022 |
Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
Topics: Blood Glucose; Comparative Effectiveness Research; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome | 2022 |
Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
Topics: Albuminuria; Blood Glucose; Cardiovascular Diseases; Comparative Effectiveness Research; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Drug Therapy, Combination; Dyslipidemias; Glomerular Filtration Rate; Glycated Hemoglobin; Heart Failure; Humans; Hypertension; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Microvessels; Sitagliptin Phosphate; Sulfonylurea Compounds | 2022 |
Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
Topics: Adult; Albuminuria; Diabetes Mellitus, Type 2; Disease Progression; Female; Glomerular Filtration Rate; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Kidney; Kidney Diseases; Liraglutide; Male; Metformin; Middle Aged; Sitagliptin Phosphate | 2023 |
Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Life Style; Metformin; Treatment Outcome | 2023 |
62 other study(ies) available for metformin and insulin glargine
| Article | Year |
|---|---|
Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients: response to Rosenstock et al.
Topics: Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
[Intensified insulin therapy. Is there an alternative to BE count?].
Topics: Algorithms; Blood Glucose Self-Monitoring; Diabetes Mellitus; Diet, Diabetic; Dose-Response Relationship, Drug; Drug Administration Schedule; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Postprandial Period; Randomized Controlled Trials as Topic | 2006 |
Some effect of metformin on insulin resistance in an infant with leprechaunism.
Topics: Abnormalities, Multiple; Fatal Outcome; Humans; Hyperglycemia; Hypoglycemic Agents; Infant, Newborn; Insulin; Insulin Glargine; Insulin Resistance; Insulin, Long-Acting; Male; Metformin | 2006 |
Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial.
Topics: Administration, Oral; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Germany; Health Care Costs; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; National Health Programs; Randomized Controlled Trials as Topic; Sulfonylurea Compounds | 2008 |
Management of type 2 diabetes mellitus associated with pituitary gigantism.
Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Diabetes Mellitus, Type 2; Ergolines; Gigantism; Human Growth Hormone; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Pituitary Neoplasms; Radiotherapy | 2007 |
Type 2 diabetes: the end of clinical inertia.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Nebulizers and Vaporizers; Peptides; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2007 |
[New data on hypoglycemia risk and beta cell function].
Topics: C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin-Secreting Cells; Insulin, Long-Acting; Metformin; Peptides; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Venoms; Weight Gain; Weight Loss | 2007 |
Psoriatic exacerbation associated with insulin therapy.
Topics: Aged; Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Middle Aged; Psoriasis | 2008 |
Is exenatide improving the treatment of type 2 diabetes? Analysis of the individual clinical trials with exenatide.
Topics: Animals; Clinical Trials as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Sulfonylurea Compounds; Venoms | 2007 |
Summaries for patients. Comparison of two types of insulin added to diabetes pills in poorly controlled type 2 diabetes.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Protamines; Sulfonylurea Compounds | 2008 |
[When oral therapy of type 2 diabetes fails--basal insulin is more effective than change in life style (interview by Dr. Thomas Meissner)].
Topics: Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Life Style; Metformin; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome | 2008 |
Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Middle Aged; Multicenter Studies as Topic; Peptides; Randomized Controlled Trials as Topic; Reproducibility of Results; Risk Assessment; Sulfonylurea Compounds; Venoms | 2009 |
Redefining insulin therapy in type 2 diabetes mellitus.
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin-Secreting Cells; Insulin, Long-Acting; Metformin | 2004 |
[Glargine insulin and cancer risk].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Breast Neoplasms; Diabetes Complications; Diabetes Mellitus; Dose-Response Relationship, Drug; Europe; Female; Humans; Insulin; Insulin Glargine; Insulin, Long-Acting; Mammary Neoplasms, Experimental; Metformin; Middle Aged; Randomized Controlled Trials as Topic; Rats; Young Adult | 2009 |
[Sequential treatment with insulin glargine and metformin, and exenatide in a patient with newly diagnosed type-2 diabetes].
Topics: Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Exercise; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Recurrence; Venoms | 2010 |
Direct healthcare costs of patients with type 2 diabetes using long-acting insulin analogues or NPH insulin in a basal insulin-only regimen.
Topics: Adolescent; Adult; Ambulatory Care; Chi-Square Distribution; Child; Child, Preschool; Cost-Benefit Analysis; Denmark; Diabetes Mellitus, Type 2; Drug Costs; Female; General Practice; Health Care Costs; Humans; Hypoglycemic Agents; Infant; Infant, Newborn; Insulin; Insulin Detemir; Insulin Glargine; Insulin, Isophane; Insulin, Long-Acting; Logistic Models; Male; Metformin; Middle Aged; Models, Economic; Odds Ratio; Outcome and Process Assessment, Health Care; Pharmaceutical Services; Primary Health Care; Propensity Score; Referral and Consultation; Registries; Time Factors; Treatment Outcome; Young Adult | 2010 |
Effective switch from premixed to basal-prandial insulin to achieve glycemic goals in type 2 diabetes.
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Obesity | 2010 |
Can postprandial blood glucose excursion be predicted in type 2 diabetes?
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Female; Gas Chromatography-Mass Spectrometry; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Postprandial Period; Sulfonylurea Compounds | 2010 |
Individualised incretin-based treatment for type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2010 |
Metformin and cancer occurrence in insulin-treated type 2 diabetic patients.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Neoplasms; Sulfonylurea Compounds | 2011 |
Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?
Topics: Aged; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Thiazolidinediones; Venoms | 2011 |
Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells?
Topics: Animals; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Randomized Controlled Trials as Topic; Thiazolidinediones; Venoms | 2011 |
Insulin management of type 2 diabetes mellitus.
Topics: Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Family Practice; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Pain; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Treatment Outcome; Weight Gain | 2011 |
Can a protocol for glycaemic control improve type 2 diabetes outcomes after gastric bypass?
Topics: Adolescent; Adult; Aged; Algorithms; Blood Glucose; Clinical Protocols; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Feasibility Studies; Female; Follow-Up Studies; Gastric Bypass; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Postoperative Period; Young Adult | 2012 |
Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; France; Humans; Hypoglycemic Agents; Incidence; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Mortality; National Health Programs; Neoplasms; Risk; Sulfonylurea Compounds; Young Adult | 2012 |
Low hemoglobin A(1c)--good diabetic control?
Topics: Anemia; Diabetes Mellitus, Type 2; Erythropoietin; Female; Glycated Hemoglobin; Hepatitis C; Humans; Insulin Glargine; Insulin, Long-Acting; Interferon-alpha; Metformin; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
The diabetologist/cardiologist debate: a meeting of the minds.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Metformin; Practice Guidelines as Topic; Precision Medicine | 2012 |
Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells.
Topics: Adolescent; Apoptosis; Cell Line, Tumor; Cell Proliferation; Child; Child, Preschool; Daunorubicin; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Aspart; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-akt; Rosiglitazone; Thiazolidinediones; TOR Serine-Threonine Kinases | 2012 |
Choosing a blood-glucose-lowering agent after metformin.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatment.
Topics: Aged; Biomarkers; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin-Secreting Cells; Insulin, Long-Acting; Male; Metformin; Middle Aged; Postprandial Period; Proinsulin; Sulfonylurea Compounds; Time Factors; Treatment Outcome | 2012 |
[Basal insulin and GLP-1 agonist potentiate each other (interview by Dr. med Dirk Einecke)].
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Injections, Subcutaneous; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Randomized Controlled Trials as Topic | 2012 |
[Early insulin treatment in type 2 diabetes--yes].
Topics: Administration, Oral; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Early Medical Intervention; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Glargine; Insulin, Long-Acting; Life Style; Metformin; Prediabetic State; Weight Loss | 2013 |
Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Fasting; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Metformin; Middle Aged; Peptides; Piperidines; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Failure; Triazoles; Venoms | 2014 |
Comparison of three algorithms for initiation and titration of insulin glargine in insulin-naive patients with type 2 diabetes mellitus.
Topics: Aged; Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Sulfonylurea Compounds | 2014 |
Predictors of response to early basal insulin treatment in patients with type 2 diabetes--the EARLY experience.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Detemir; Insulin Glargine; Insulin, Long-Acting; Male; Maximum Tolerated Dose; Metformin; Predictive Value of Tests; Prospective Studies; Treatment Outcome | 2014 |
Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
Topics: Aged; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Female; Germany; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Prospective Studies; Time Factors; Treatment Outcome | 2013 |
[Researchers illuminate diabetes therapy].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin | 2014 |
Is insulin the most effective injectable antihyperglycaemic therapy?
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Fasting; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Peptides; Treatment Outcome; Venoms | 2015 |
The effects of insulin and liraglutide on osteoprotegerin and vascular calcification in vitro and in patients with type 2 diabetes.
Topics: Aged; Alkaline Phosphatase; Cells, Cultured; Core Binding Factor Alpha 1 Subunit; Coronary Vessels; Diabetes Mellitus, Type 2; Endpoint Determination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; In Vitro Techniques; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Muscle, Smooth, Vascular; Osteoprotegerin; Pilot Projects; Prospective Studies; Sialoglycoproteins; Vascular Calcification | 2015 |
How much is too much? Outcomes in patients using high-dose insulin glargine.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Weight Gain | 2016 |
A patient centred approach to basal insulin choice for the management of type 2 diabetes mellitus.
Topics: Checklist; Clinical Decision-Making; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Insulin Detemir; Insulin Glargine; Insulin, Isophane; Insulin, Long-Acting; Metformin; Patient-Centered Care | 2016 |
Comparison of insulin intensification strategies with insulin lispro low mixture twice daily versus basal insulin glargine and prandial insulin lispro once daily in East Asian and Caucasian patients with type 2 diabetes mellitus.
Topics: Aged; Asia, Eastern; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin Lispro; Male; Metformin; Middle Aged; Multicenter Studies as Topic; Outcome Assessment, Health Care; Pioglitazone; Postprandial Period; Randomized Controlled Trials as Topic; Thiazolidinediones; White People | 2017 |
[Acidosis without marked hyperglycemia : Euglycemic diabetic ketoacidosis associated with SGLT2-Inhibitors].
Topics: Benzhydryl Compounds; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes.
Topics: Adipose Tissue; Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Bilirubin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Insulin Lispro; Liver; Magnetic Resonance Imaging; Male; Metformin; Middle Aged; Pioglitazone; Polyethylene Glycols; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides | 2016 |
Growth Differentiation Factor 15 as a Novel Biomarker for Metformin.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glycated Hemoglobin; Growth Differentiation Factor 15; Humans; Hypoglycemic Agents; Insulin Glargine; Logistic Models; Metformin; Polymorphism, Single Nucleotide | 2017 |
Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
Topics: Acute Disease; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin Glargine; Male; Metformin; Middle Aged; Pancreatitis; Peptides; Recombinant Fusion Proteins; Sitagliptin Phosphate; Venoms | 2017 |
Effectiveness and clinical inertia in patients with antidiabetic therapy.
Topics: Adult; Aged; Colombia; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies | 2017 |
Simulation-Based Evaluation of Dose-Titration Algorithms for Rapid-Acting Insulin in Subjects with Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antihyperglycemic Medications.
Topics: Algorithms; Computer Simulation; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin Lispro; Metformin; Models, Theoretical | 2017 |
Reply.
Topics: Body Weight; Diabetes Mellitus, Type 2; Humans; Insulin Glargine; Lipids; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Sitagliptin Phosphate | 2019 |
Letter to Editor: Role of Pharmacotherapy in Patients With Coexisting Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
Topics: Body Weight; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Glargine; Lipids; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Sitagliptin Phosphate | 2019 |
Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes.
Topics: Body Weight; Diabetes Mellitus, Type 2; Humans; Incretins; Insulin Glargine; Lipids; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Sitagliptin Phosphate | 2019 |
Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Insulin Glargine; Insulin Resistance; Male; Metformin; Middle Aged | 2019 |
Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.
Topics: Adult; Arginine; B-Lymphocytes; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Withholding Treatment | 2019 |
Letter to the Editor: Intrahepatic Lipid Content After Insulin Glargine Addition to Metformin in Type II Diabetes Mellitus With Nonalcoholic Fatty Liver Disease.
Topics: Body Weight; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Glargine; Lipids; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Sitagliptin Phosphate | 2020 |
Reply.
Topics: Body Weight; Diabetes Mellitus, Type 2; Humans; Insulin Glargine; Lipids; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Sitagliptin Phosphate | 2020 |
Comparative effects of lifestyle modification, metformin and exenatide/glargine combination therapy on daily glycaemic fluctuation in the setting of near-normoglycaemia.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Life Style; Metformin; Venoms | 2020 |
Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study.
Topics: Acute Coronary Syndrome; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Glycemic Index; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Liraglutide; Male; Metformin; Middle Aged; Pilot Projects; Random Allocation; Spain | 2020 |
An Escape From Diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Insulin Glargine; Metformin | 2020 |
Effects of antidiabetic agents on Alzheimer's disease biomarkers in experimentally induced hyperglycemic rat model by streptozocin.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Biomarkers; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Donepezil; Glucose; Glyburide; Glycated Hemoglobin; Hypoglycemic Agents; Insulin Glargine; Male; Malondialdehyde; Metformin; Microtubule-Associated Proteins; Nitric Oxide; Rats; Rats, Wistar; Streptozocin; Triglycerides; Tumor Necrosis Factor-alpha | 2022 |
Emulating the GRADE trial using real world data: retrospective comparative effectiveness study.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome | 2022 |
[In patients with type 2 diabetes on metformin, the addition of which antihyperglycemic class among a sulfonylurea (glimepiride), a DPP-4 inhibitor (sitagliptin), a GLP-1 agonist (liraglutide), or basal insulin (glargine) is the most effective to achieve
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycemic Control; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Liraglutide; Metformin; Sitagliptin Phosphate; Treatment Outcome | 2023 |
In type 2 diabetes, glargine and liraglutide each improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Sitagliptin Phosphate; Treatment Outcome | 2023 |